We have used a double‐labelling flow cytometry analysis of keratin (CK) and DNA in breast cancer. Five monoclonal anti‐keratin antibodies were tested: KL1 recognizing Mr 55,000–57,000 keratins, and “anti‐glandular epithelia,” LE41, RGE‐53, and LP2K specific for CK n° 7, 8, 18, and 19 of Moll's classification, respectively. Flow cytometric (DNA‐CK) analysis was performed on 10 benign and 19 malignant human breast tumors. All the benign tumors were diploid and 63% of the malignant tumors were aneuploid. This technique permits the analysis of DNA in the epithelial fraction alone. In aneuploid tumors, gating the DNA‐keratin‐positive population allowed accurate DNA analysis without interference due to debris background and non‐epithelial cells. Moreover, double‐labelling using the CK19 antibody gave a better identification of near‐diploid tumors. An enhancement of keratin expression in malignant tumors was observed with CK 19 (P < 0.001), KL1 (P < 0.01), CK 8 (P < 0.05), and CK18 (n.s.) compared to benign tumors. The comparison of keratin expression in aneuploid and diploid malignant tumors revealed reduced CK8, CK18, and CK19 in the former.
Using four human tumor cell lines, MCF-7 and T47-D from breast tumors, MOLT-4 and K-562 from leukemia, flow cytometric DNA analysis of pure and mixed cell population was performed using monoclonal antibodies to cytokeratin to distinguish cytokeratin-containing carcinoma cells from leukemia cells which do not contain cytokeratins. Surprisingly, on pure or mixed K-562 cells, we found positive labeling with KL1, CK8, and CK18 antibodies (results confirmed by immunocytology). This preliminary study has allowed a DNA analysis on epithelial cells of human breast tumors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.